"Heparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
| Descriptor ID |
D006493
|
| MeSH Number(s) |
D09.698.373.400
|
| Concept/Terms |
Heparin- Heparin
- Unfractionated Heparin
- Heparin, Unfractionated
- Heparinic Acid
|
Below are MeSH descriptors whose meaning is more general than "Heparin".
Below are MeSH descriptors whose meaning is more specific than "Heparin".
This graph shows the total number of publications written about "Heparin" by people in this website by year, and whether "Heparin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 2 | 1 | 3 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 1 | 3 |
| 2000 | 1 | 2 | 3 |
| 2001 | 3 | 6 | 9 |
| 2002 | 0 | 3 | 3 |
| 2003 | 4 | 0 | 4 |
| 2004 | 5 | 2 | 7 |
| 2005 | 2 | 1 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 2 | 4 |
| 2008 | 2 | 3 | 5 |
| 2009 | 4 | 2 | 6 |
| 2010 | 2 | 2 | 4 |
| 2011 | 2 | 3 | 5 |
| 2012 | 7 | 1 | 8 |
| 2013 | 7 | 1 | 8 |
| 2014 | 5 | 2 | 7 |
| 2015 | 4 | 1 | 5 |
| 2016 | 3 | 0 | 3 |
| 2017 | 2 | 3 | 5 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 3 | 5 |
| 2020 | 1 | 4 | 5 |
| 2021 | 2 | 2 | 4 |
| 2022 | 2 | 6 | 8 |
| 2023 | 1 | 4 | 5 |
| 2024 | 2 | 0 | 2 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heparin" by people in Profiles.
-
Dosing Reliability of Direct Thrombin Inhibitors in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis. ASAIO J. 2025 Sep 01; 71(9):691-700.
-
Bivalirudin Versus Heparin in Patients Undergoing Percutaneous Coronary Intervention in Acute Coronary Syndromes. Crit Pathw Cardiol. 2025 Mar 01; 24(1):e0372.
-
Discordance between aPTT and anti-Xa in monitoring heparin anticoagulation in mechanical circulatory support. ESC Heart Fail. 2024 Oct; 11(5):2742-2748.
-
Thromboelastography versus thromboelastometry for unfractionated heparin monitoring in adult patients on extracorporeal membrane oxygenation. Perfusion. 2025 01; 40(1):235-242.
-
Systemic anticoagulation in ECMO. Semin Pediatr Surg. 2023 Aug; 32(4):151333.
-
Safety of routine protamine in the reversal of heparin in percutaneous coronary intervention: A systematic review and meta-analysis. Int J Cardiol. 2023 10 01; 388:131168.
-
Evaluation of acquired antithrombin deficiency in paediatric patients supported on extracorporeal membrane oxygenation. Br J Clin Pharmacol. 2023 08; 89(8):2396-2406.
-
Correlation between partial thromboplastin time and thromboelastography in adult critically ill patients requiring bivalirudin for extracorporeal membrane oxygenation. Pharmacotherapy. 2023 03; 43(3):196-204.
-
The History of Extracorporeal Membrane Oxygenation and the Development of Extracorporeal Membrane Oxygenation Anticoagulation. Semin Thromb Hemost. 2024 Feb; 50(1):81-90.
-
The effects of heparin, aspirin, and maternal clinical factors on the rate of nonreportable cell-free DNA results: a retrospective cohort study. Am J Obstet Gynecol MFM. 2023 03; 5(3):100846.